Precision BioSciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precision BioSciences, Inc. on July 6, 2020. The report discloses the termination of a material definitive agreement with Gilead Sciences regarding a collaboration on hepatitis B virus treatments.
Key Financial Metrics
This filing does not contain current period revenue, profit, cash flow, or liquidity metrics. However, it references the financial terms of the terminated agreement:
- Research Funding: Up to approximately $40 million over an initial three-year term.
- Milestone Payments: Up to an aggregate of $445 million (comprising up to $105.0 million in development milestones and up to $340.0 million in commercial milestones).
- Royalties: Tiered royalties ranging from high single-digit to mid-teen percentages on worldwide net sales.
Material Changes
On July 6, 2020, Gilead Sciences notified Precision BioSciences of its termination of the Collaboration and License Agreement dated September 10, 2018 (as amended). The agreement will terminate effective September 4, 2020. Upon termination, Precision BioSciences will regain full rights and all data generated for the in vivo chronic hepatitis B virus program developed under the agreement.
Outlook, Risks, and Management Commentary
The termination eliminates the potential for future milestone payments and royalties associated with the Gilead collaboration. The company has updated its corporate deck, available on its investor relations website, to reflect this change. No specific guidance or forward-looking financial projections were provided in this filing.
Key Facts for Investor Verification
- Confirm the effective termination date of September 4, 2020, and the immediate impact on the company's cash flow projections.
- Verify the status of the in vivo chronic hepatitis B virus program and the company's strategy for monetizing the regained rights and data.
- Review the updated corporate deck referenced in Item 7.01 for revised strategic priorities.
- Assess the impact of losing the Gilead partnership on the company's overall pipeline valuation and future funding requirements.